Baxter International BAX Pharmaceuticals — Research and development expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's pharmaceuticals — research and development expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's pharmaceuticals — research and development expenses?
- Baxter International (BAX) reported pharmaceuticals — research and development expenses of $22M in Q1 2026.
- How has Baxter International's pharmaceuticals — research and development expenses changed year-over-year?
- Baxter International's pharmaceuticals — research and development expenses decreased by 15.4% year-over-year, from $26M to $22M.
- What is the long-term trend for Baxter International's pharmaceuticals — research and development expenses?
- Over 3 years (2022 to 2025), Baxter International's pharmaceuticals — research and development expenses has grown at a 7.6% compound annual growth rate (CAGR), from $81M to $101M.
- What does pharmaceuticals — research and development expenses mean?
- The amount spent on developing new products and improving existing ones within the Pharmaceuticals segment.
- How do you interpret pharmaceuticals — research and development expenses?
- Higher spending indicates a commitment to future growth and innovation, though it reduces short-term operating income.
- How does pharmaceuticals — research and development expenses compare across companies?
- Highly variable based on the stage of the product pipeline; peers in pharma typically maintain high R&D intensity.